Posted by Michael Wonder on 21 Oct 2019
Proposal to award sole supply for fluticasone and fluticasone with salmeterol metered dose inhalers
21 October 2019 - PHARMAC is seeking feedback on a proposal to make changes to the funded brands of fluticasone and fluticasone with salmeterol metered dose inhalers, which are used in the treatment of asthma and chronic obstructive pulmonary disease.
These changes would mean that only the Flixotide and Seretide brands would be funded from 1 September 2020, following a six-month transition period.
These changes would mean that most people using fluticasone and fluticasone with salmeterol metered dose inhalers (approximately 220,000 people) would remain on their currently funded brand, but a small proportion of people (about 5%) using the Floair and RexAir brands would need to change to the Flixotide and Seretide brands in order to remain on a fully funded brand.
